Key result
Direct oral anticoagulants administered in the acute phase after mechanical thrombectomy resulted in a 0% rate of recurrent cerebral infarction and a 0% rate of symptomatic bleeding at 30 days, compared to 2.8% for both outcomes with warfarin.
Why the study?
Usage of oral anticoagulants in the acute phase of cerebral infarction has increased, but the optimal timing for starting them after mechanical thrombectomy remains unclear.
Do DOACs compared to warfarin reduce intracranial hemorrhage and recurrent cerebral infarction in patients after mechanical thrombectomy for anterior circulatory embolism?
Cohort (n=64)
No
Do DOACs compared to warfarin reduce intracranial hemorrhage and recurrent cerebral infarction in patients after mechanical thrombectomy for anterior circulatory embolism?
DOACs appear safe and effective when initiated in the acute phase following mechanical thrombectomy for anterior circulatory embolism, with low rates of bleeding and recurrent infarction compared to warfarin.
Objective: The usage of oral anticoagulants (OACs) in the acute phase of cerebral infarction has increased, but the optimal timing for starting OACs after mechanical thrombectomy (MT) is unclear. We report the usage of OACs after MT at our hospital and evaluated the outcomes. Methods: OACs were selected as secondary preventive drugs for 64 patients who underwent MT for anterior circulatory embolism between July 2016 and January 2019. Of the 64 patients, 28 and 36 received direct oral anticoagulants (DOACs) and warfarin (Wf), respectively. We compared the frequency of intracranial hemorrhage in the acute phase and that of recurrent cerebral infarction within 30 days. Results: The median diffusion-weighted imaging-Alberta Stroke Program Early Computed Tomography Scores + white matter (DWI-ASPECTS + W) score at admission was 7.5 (IQR 6-9)/8 (IQR, 6-9) in the DOACs group/Wf group. The rate of recanalization with modified thrombolysis in cerebral infarction (TICI) ≥2B by MT was 89.3/80.6%. In patients with subarachnoid hemorrhage (SAH) associated with MT and patients with hemorrhagic transformation (HT) on MRI the next day, administration was started after hemostasis. The median timing of the first anticoagulant administration was 3 (IQR, 2-4)/2 (IQR, 1-4) days. In the case of no HT the next day, the rate of new HT after 1 week was 7.1%/29.1%. In the case of HT the next day, the rate of HT deterioration the next day was 7.1%/16.6%. The percentage of symptomatic bleeding was 0%/2.8%. The percentage of recurrent cerebral infarction within 30 days was 0%/2.8%. Conclusion: OACs in the acute phase after MT can be safely used and are expected to be effective at preventing recurrence.
No takes yet. Share an insight, caveat, or question.
Shindo et al. (2020) conducted a cohort in Acute phase after mechanical thrombectomy for anterior circulatory embolism (n=64). Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on Recurrent cerebral infarction within 30 days (p=NS). Direct oral anticoagulants administered in the acute phase after mechanical thrombectomy resulted in a 0% rate of recurrent cerebral infarction and a 0% rate of symptomatic bleeding at 30 days, compared to 2.8% for both outcomes with warfarin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: